Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 8/20 | 0.53 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322754 | 0.88 | CCR4 (0.51) | CCR4CCR5OPRM1 | |
| SCHEMBL24322708 | 0.85 | OPRM1 (0.54) | CCR4CCR5KCNH2OPRM1 | |
| SCHEMBL24322373 | 0.83 | CCR4 (0.50) | CCR4CCR5KCNH2OPRM1 | |
| SCHEMBL24322461 | 0.82 | CCR4 (0.55) | CCR4CCR5OPRM1 | |
| SCHEMBL24322905 | 0.81 | CCR4 (0.54) | CCR4CCR5KCNH2OPRM1 | |
| SCHEMBL24322750 | 0.81 | SIGMAR1 (0.56) | CCR4CCR5KCNH2OPRM1 | |
| SCHEMBL24323862 | 0.73 | HTR6 (0.47) | — | |
| SCHEMBL24322530 | 0.73 | OPRM1 (0.58) | KCNH2OPRM1 | |
| SCHEMBL24322900 | 0.72 | ALDH1A1 (0.50) | CCR5KCNH2TACR3 | |
| Pipramadol SCHEMBL2111004 | 0.71 | CCR5 (0.48) | CCR4CCR5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | CCR4 3820/4885CCR5 1812/4885KCNH2 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.